Civitas Therapeutics Inc., which launched in January with a $20 million Series A funding round, has now bumped that up to $28 million, according to federal documents.

The original filing with the U.S. Securities and Exchange Commission in January  shows that Civitas had taken $10 million of the $20 million committed funding from backers that include co-lead investors Longitude Capital, which has an office in Greenwich, Conn., and Canaan Partners. The latest filing posted today shows that Civitas has now taken in $14 million and that the top end of the Series A round has jumped to $28 million.

SOURCE